{
  "source": "PA-Notification-Kineret.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1055-14\nProgram Prior Authorization/Notification\nMedication Kineret® (anakinra)\nP&T Approval Date 1/2007, 6/2008 , 4/2009, 6/2009, 12/2009, 7/2010, 11/2010, 7/2011,\n11/2011, 7/2012, 11/2012, 2/2013, 2/2014, 2/2015, 3/2016, 3/2017,\n3/2018, 3/2019, 3/2020, 3/2021, 3/2022, 3/2023, 7/2023, 10/2024\nEffective Date 1/1/2025\n1. Background:\nKineret (anakinra) is an interleukin-1 receptor antagonist indicated for moderately to severely\nactive rheumatoid arthritis in patients 18 years of age or older who have failed one or more\ndisease-modifying anti-rheumatic drugs (DMARDs).1 Examples of DMARDs commonly\nused in the treatment of rheumatoid arthritis include methotrexate, leflunomide, and\nsulfasalazine.2,6 Kineret is also indicated for the treatment of Neonatal-Onset Multisystem\nInflammatory Disease (NOMID) and the treatment of deficiency of interleukin-1 receptor\nantagonist (DIRA).1 Clinical evidence also supports the use of Kineret to treat active\nsystemic juvenile idiopathic arthritis and adult onset Still’s disease.3,4,7, 8\n2. Coverage Criteriaa:\nA. Rheumatoid Arthritis (RA)\n1. Initial Authorization\na. Kineret will be approved based on all of the following criteria:\n(1) Diagnosis of moderately to severely active rheumatoid arthritis\n-AND-\n(2) Patient has had an inadequate response to one or more disease-modifying anti-\nrheumatic drugs (DMARDs) (e.g., methotrexate, leflunomide, and\nsulfasalazine)\n-AND-\n(3) Patient is not receiving Kineret in combination with another targeted\nimmunomodulator. [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi\n(golimumab), Orencia (abatacept), Xeljanz (tofacitinib), Olumiant (baricitinib),\nRinvoq (upadacitinib)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Kineret will be approved based on both of the following criteria:\n© 2024 UnitedHealthcare Services, Inc.\n1\n(1) Documentation of positive clinical response to Kineret therapy\n-AND-\n(2) Pati",
    "rization\na. Kineret will be approved based on both of the following criteria:\n© 2024 UnitedHealthcare Services, Inc.\n1\n(1) Documentation of positive clinical response to Kineret therapy\n-AND-\n(2) Patient is not receiving Kineret in combination with another targeted\nimmunomodulator. [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi\n(golimumab), Orencia (abatacept), Xeljanz (tofacitinib), Olumiant (baricitinib),\nRinvoq (upadacitinib)]\nAuthorization will be issued for 12 months.\nB. Neonatal-Onset Multisystem Inflammatory Disease (NOMID)\n1. Initial Authorization\na. Kineret will be approved based on both of the following criteria:\n(1) Diagnosis of neonatal-onset multisystem inflammatory disease (NOMID)\n-AND-\n(2) Patient is not receiving Kineret in combination with another targeted\nimmunomodulator. [e.g., Enbrel (etanercept), Cimzia (certolizumab),\nSimponi (golimumab), Orencia (abatacept), Xeljanz (tofacitinib), Olumiant\n(baricitinib), Rinvoq (upadacitinib)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Kineret will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Kineret therapy\n-AND-\n(2) Patient is not receiving Kineret in combination with another targeted\nimmunomodulator. [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi\n(golimumab), Orencia (abatacept), Xeljanz (tofacitinib), Olumiant (baricitinib),\nRinvoq (upadacitinib)]\nAuthorization will be issued for 12 months.\nC. Systemic Juvenile Idiopathic Arthritis\n1. Initial Authorization\na. Kineret will be approved based on both of the following criteria:\n© 2024 UnitedHealthcare Services, Inc.\n2\n(1) Diagnosis of active systemic juvenile idiopathic arthritis (formerly Still’s\ndisease)\n-AND-\n(2) Patient is not receiving Kineret in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),\nSimponi (golimumab), Orencia (abatacept), Xeljanz (tofacitinib), Olumiant\n(baricitinib), Rinvoq (upadacitin",
    "ion with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),\nSimponi (golimumab), Orencia (abatacept), Xeljanz (tofacitinib), Olumiant\n(baricitinib), Rinvoq (upadacitinib)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Kineret will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Kineret therapy\n-AND-\n(2) Patient is not receiving Kineret in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi\n(golimumab), Orencia (abatacept), Xeljanz (tofacitinib), Olumiant (baricitinib),\nRinvoq (upadacitinib)]\nAuthorization will be issued for 12 months.\nD. Adult Onset Still’s Disease\n1. Initial Authorization\na. Kineret will be approved based on both of the following criteria:\n(1) Diagnosis of adult onset Still’s Disease\n-AND-\n(2) Patient is not receiving Kineret in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi\n(golimumab), Orencia (abatacept), Xeljanz (tofacitinib), Olumiant (baricitinib),\nRinvoq (upadacitinib)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Kineret will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Kineret therapy\n-AND-\n© 2024 UnitedHealthcare Services, Inc.\n3\n(3) Patient is not receiving Kineret in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),\nSimponi (golimumab), Orencia (abatacept), Xeljanz (tofacitinib), Olumiant\n(baricitinib), Rinvoq (upadacitinib)]\nAuthorization will be issued for 12 months.\nE. Deficiency of Interleukin-1 Receptor Antagonist (DIRA)\n1. Initial Authorization\na. Kineret will be approved based on both of the following criteria:\n(1) Diagnosis of deficiency of Interleukin-1 Receptor Antagonist (DIRA)\n-AND-\n(2) Patient is not receiving Kineret in combination with another targeted\nimmunomodulator [",
    "oth of the following criteria:\n(1) Diagnosis of deficiency of Interleukin-1 Receptor Antagonist (DIRA)\n-AND-\n(2) Patient is not receiving Kineret in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi\n(golimumab), Orencia (abatacept), Xeljanz (tofacitinib), Olumiant (baricitinib),\nRinvoq (upadacitinib)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Kineret will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Kineret therapy\n-AND-\n(2) Patient is not receiving Kineret in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi\n(golimumab), Orencia (abatacept), Xeljanz (tofacitinib), Olumiant (baricitinib),\nRinvoq (upadacitinib)]\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n© 2024 UnitedHealthcare Services, Inc.\n4\n• Supply limits may be in place.\n4. References:\n1. Kineret [package insert]. Waltham, MA: Sobi; December 2020.\n2. Pavy S. Constantin A, Pham T, et al. Methotrexate therapy for rheumatoid arthritis: clinical\npractice guidelines based on published evidence and expert opinions. Joint Bone Spine\n2006;73(4):388-95.\n3. Beukelman T, Patkar NM, Saag KG, et al. 2011 American College of Rheumatology\nrecommendations for the treatment of juvenile idiopathic arthritis: initiation and safety\nmonitoring of therapeutic agents for the treatment of arthritis and systemic features. ",
    "ollege of Rheumatology\nrecommendations for the treatment of juvenile idiopathic arthritis: initiation and safety\nmonitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care\nRes. 2011 Apr;63(4):465-82.\n4. Quartier P, Allantaz, Cimaz R, et al. A multicenter, randomized, double-blind, placebo-controlled\ntrial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile\nidiopathic arthritis (ANAJIS trial). Ann Rheum Dis. 2011 May;70(5):747-54.\n5. Yu JR and Leslie KS. Cryopyrin-associated periodic syndrome: an update on diagnosis and\ntreatment response. Curr Allergy Asthma Rep. 2011;11(1):12-20.\n6. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology Guideline\nfor the Treatment of Rheumatoid Arthritis. Arthritis Care & Research. 2021; 73(7):934-939.\n7. Ringold S, et al. 2013 update of the 2011 American College of Rheumatology recommendations\nfor the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of\nchildren with systemic juvenile idiopathic arthritis and tuberculosis screening among children\nreceiving biologic medications. Arthritis Rheum. 2013 Oct;65(10):2499-512.\n8. Mandl LA. Treatment of adult-onset Still’s disease. In: UpToDate, Waltham, MA, August 2021.\nProgram Prior Authorization/Notification - Kineret\nChange Control\n2/2014 Reauthorization criteria revised to include concomitant therapy\ncriterion. Extended reauthorization duration to 24 months.\n9/2014 Administrative change - Tried/Failed exemption for State of New Jersey\nremoved.\n2/2015 Annual reviewed. Updated NOMID criteria to align with other CAPS\nprograms. Minor reformatting. Updated references.\n3/2016 Annual review. Updated criteria for NOMID to match section 1 of\npacket insert. Updated reference.\n3/2017 Annual review with no changes to clinical criteria. Updated\nbackground and references.\n3/2018 Annual review with no changes to clinical criteria. Updated references.\n3/2019 ",
    " Updated reference.\n3/2017 Annual review with no changes to clinical criteria. Updated\nbackground and references.\n3/2018 Annual review with no changes to clinical criteria. Updated references.\n3/2019 Annual review. Added Olumiant (baricitinib) to list of medications that\npatient should not be receiving while on Kineret therapy for rheumatoid\narthritis. Updated references.\n3/2020 Annual review. Added criteria for adult onset Still’s disease. Updated\nreference.\n3/2021 Annual review. Updated background information to reflect package\ninsert. Added coverage criteria for the treatment of Deficiency of\nInterleukin-1 Receptor Antagonist (DIRA). Updated reauthorization to\n12 months to reflect other programs. Updated references.\n3/2022 Annual review. Updated references.\n© 2024 UnitedHealthcare Services, Inc.\n5\n3/2023 Annual review with no update to coverage criteria. Changed Humira\nexamples to adalimumab and added Rinvoq as a JAKI example Added\nstate mandate footnote.\n7/2023 Updated not receiving in combination language to targeted\nimmunomodulator and updated examples.\n10/2024 Annual review with no change to coverage criteria.\n© 2024 UnitedHealthcare Services, Inc.\n6"
  ]
}